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Abstract
Background and Aims: It is currently unknown whether Cy-
toSorb treatment for septic shock improves long-term sur-
vival beyond 28 days from intensive care unit (ICU) admis-
sion and which factors determine outcome. Methods: This 
was a long-term follow-up retrospective analysis of patients 
with septic shock who were treated with continuous renal 
replacement therapy (CRRT) + CytoSorb (n = 67) or CRRT 
alone (n = 49). These patients were previously analyzed for 
28-day mortality. The primary outcome was the time to long-
term all-cause mortality. Factors associated with time to 
event were analyzed both weighted by stabilized inverse 
probability of treatment weights (sIPTW) as well as un-
weighted stratified by therapy received. Results: The medi-
an follow-up for the total cohort was 30 days (interquartile 
range [IQR]: 5–334, maximum 1,059 days) after ICU admis-
sion and 333 days (IQR: 170–583) for those who survived be-
yond 28 days (n = 59). Survival beyond 28 days was sustained 
up to 1 year after ICU admission for both treatment regi-
mens: 80% (standard error [SE] 7%) vs. 87% (SE 7%), for Cy-
toSorb vs. CRRT, respectively, p = 0.853. By sIPTW, CytoSorb 
was significantly associated with long-term outcome com-
pared to CRRT (adjusted hazard ratio [aHR] 0.59, 95% confi-
dence interval [CI] 0.37–0.93, p = 0.025). Independent factors 
associated with long-term outcome in CytoSorb-treated pa-
tients were baseline log10 lactate levels (aHR 5.1, p = 0.002), 
age in the presence of comorbidity (aHR 2.60, p = 0.013), and 
presence of abdominal sepsis (aHR 0.34, p = 0.004). A lactate 
level above 6.0 mmol/L at the start of CytoSorb therapy had 
a positive predictive value of 79% for mortality (p = 0.013). 
Conclusions: Survival is achieved with CytoSorb and CRRT 
for patients with septic shock beyond 28 days from ICU ad-
mission and may be improved for CytoSorb treatment. Lac-
tate levels above 6.0 mmol/L at the start of CytoSorb therapy 
are predictive of worse outcome with high specificity and 
positive predictive value. © 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Worldwide, approximately 45 million patients suffer 
from sepsis with an estimated 11 million deaths each year 
[1–4]. Sepsis and septic shock are the leading causes of 
mortality with an amplified incidence due to increased 
aging of populations, comorbidities, and greater aware-
ness of sepsis, but also because of emerging pandemics [5, 
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6]. Septic shock arises from a derailed host response to 
infection, with consequently a condition what is known 
as a “cytokine storm” leading to shock [6]. Sepsis is gener-
ally treated with early resuscitation and antibiotics, which 
is strongly associated with an improved outcome [5]. 
More innovative treatment options have been evaluated, 
most with disappointing results. Continuous renal re-
placement therapy (CRRT) proved able to clear cytokines 
from serum and possibly improve the cytokine storm; 
however, a clinical benefit seems to be lacking [7–9]. Re-
cently, we have shown that CytoSorb treatment may lead 
to an improved clinical outcome at 28 days from intensive 
care unit (ICU) admission for refractory septic shock 
[10]. CytoSorb has been developed and approved for use 
in patients with severe cytokinemia [11–13]. It is an ad-
sorber which can be used in addition to CRRT and has 
been shown to be able to reduce circulating cytokines by 
>90% [13]. It is currently not known whether CytoSorb 
therapy for refractory septic shock is associated with an 
improved survival beyond the first month of ICU admis-
sion. Moreover, factors determining (un)favourable out-
comes and the optimal timing of CytoSorb therapy are 
currently not known. Therefore, the aim of the current 
study was to investigate the long-term outcome of the 
septic shock patients we had previously investigated for 
28-day survival who were treated with CytoSorb and/or 




This is a long-term follow-up of a retrospective cohort study, 
in which patients were treated at the ICU for septic shock with Cy-
toSorb and/or CRRT. Here, we further studied the cohort of pa-
tients we had previously studied for 28-day survival. The selection 
methods and inclusion and exclusion criteria are described else-
where in detail [10]. In short, patients admitted to the ICU with 
septic shock who were treated with CytoSorb or CRRT in the pe-
riod from January 1, 2014, to April 1, 2017, were eligible for inclu-
sion in the study. These patients were treated at the discretion of 
the attending intensive care physician according to local protocol. 
Patients were excluded from the analysis in case the primary rea-
son for therapy was not septic shock. In case of improvement of 
septic shock or renal function, CytoSorb or CRRT was discontin-
ued. CytoSorb was used according to the manufacturer’s protocol. 
It was placed in a blood-pump circuit with an optimal ultrafiltra-
tion rate of 250–400 mL/min. The CytoSorb adsorber was changed 
after 24 hours of use.
Definitions
Septic shock was defined as persisting hypotension requiring 
vasopressive medication to maintain mean arterial pressure 
(MAP) ≥65 mmHg and having a serum lactate level of >2 mmol/L 
despite adequate volume resuscitation [6]. Shock reversal was de-
fined as a serum lactate level of ≤2 mmol/L and discontinuation of 
vasopressive medication [14].
Endpoints
The primary endpoint was the time to all-cause mortality com-
pared for CytoSorb versus CRRT alone. Also, factors associated 
with all-cause mortality during long-term follow-up were analyzed 
separately. All-cause mortality was measured from ICU admission 
until the last follow-up date known (irrespective of ICU, in-hospi-
tal, or out-of-hospital mortality).
Statistical Analysis
A survival analysis was employed with application of the in-
verse probability of treatment weights (IPTW), including a stabi-
lizing method to avoid bias from extreme weights. Stabilized IPTW 
(sIPTW) is applied to overcome differences in baseline patient 
characteristics, to mimic a randomized controlled trial [15]. The 
sIPTW was previously constructed [10] and contains the following 
variables at the start of therapy: age, presence of any comorbidity, 
SOFA score, lactate level, noradrenalin level, type of sepsis, and 
medical or surgical treatment. Since mean arterial pressure (MAP) 
at the start of therapy was at imbalance between the 2 treatment 
groups and associated with outcome, it was additionally accounted 
for in the final analysis [10, 15]. Factors associated with all-cause 
mortality in CytoSorb-treated patients were analyzed as well with-
out application of sIPTW. For this, factors with a p value of <0.2 in 
univariate Cox regression analysis were considered for multivari-
ate analyses, where a full, forced and final model was constructed. 
Using the same variables from the full model, the final model was 
constructed using the back step and forward step likelihood ratio 
method, where the model with the highest χ2 value was selected. 
Moreover, factors determining outcome were selected and in-
spected for optimal clinical use by analyzing tests’ characteristics 
with Harrell’s C-statistic and for laboratory values choosing the 
optimal cutoff using the highest sensitivity and specificity sum. 
Laboratory values and variables with a skewed normal distribution 
were log-transformed prior to the analysis. SAS Enterprise version 
9.4 and SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) were used 
to perform the statistical analyses. All statistical tests were two-
sided and evaluated at the 0.05 level of significance.
Results
Patient and Follow-Up Characteristics
In total, 67 patients with septic shock were treated with 
CytoSorb, versus 49 with CRRT. Table 1 shows the patient 
characteristics at the start of therapy [10]. Patients were fol-
lowed for a median duration of 30 days (interquartile range 
[IQR]: 5–334) with a maximum of 1,059 days after ICU ad-
mission. For those patients followed beyond 28 days after 
ICU admission (n = 59), the median follow-up duration 
was 333 days (IQR: 170–583). There was no difference in 
median follow-up duration between the 2 treatment groups 
(p = 0.880). Median ICU and hospital admission were 9 and 




17–22 days, respectively, for both groups (p = 0.735 and 
p = 0.991). The mean duration from ICU admission to the 
start of treatment was 2.1 (SE 0.36) versus 1.66 (SE 0.38) 
days (p = 0.416) for CRRT versus CytoSorb, respectively. In 
the CRRT group, CRRT was given for a mean duration of 
4.96 (SE 0.63) days versus 4.97 (SE 0.55) days in the Cyto-
Sorb group (p = 0.990). The mean treatment duration for 
the CytoSorb group was 2.34 (SE 0.16) days.
CytoSorb and CRRT Lead to a Durable Response 
beyond 28 Days of ICU Admission
For the total group, at 1 year after ICU admission, the 
unweighted survival rate was similar in both groups with 
CytoSorb-treated patients being 42% (standard error 
[SE] 6%) and CRRT-treated patients, 43% (SE 7%) 
(Fig. 1a), while CytoSorb-treated patients had a more se-
vere shock as mentioned before. For those patients who 
survived beyond 28 days of ICU admission, survival for 
CytoSorb and CRRT at 1 year after ICU admission was 
comparable at 80% (SE 7%) and 87% (SE 7%), respective-
ly (p = 0.853).
CytoSorb May Improve Long-Term Outcome 
Compared to CRRT Alone
By Kaplan-Meier analysis applying sIPTW, the 1-year 
survival was 37% (SE 7%) versus 26% (SE 12%) for Cyto-
Sorb versus CRRT, respectively (log-rank p = 0.21). By 
Cox regression analysis adjusted for the MAP at baseline 
of therapy, CytoSorb treatment showed a significantly 
higher survival rate compared to CRRT (adjusted HR 
[aHR] 0.59, 95% Wald confidence interval [CI]: 0.37–0.93, 
p = 0.025; Fig. 1b). In this model, presence of chronic kid-
ney disease (aHR 1.10, p = 0.736) or gender (aHR 1.02, 
p = 0.940) were not significantly associated with outcome.
Factors Associated with Long-Term Outcome in the 
CytoSorb Group
Factors in univariable and multivariable analyses associ-
ated with outcome in the CytoSorb group can be found in 
Table 2. Noradrenaline levels did not significantly interfere 
with lactate levels (p = 0.496). However, there was evidence 
of collinearity for noradrenaline and lactate levels. When 
lactate was replaced by noradrenaline, the multivariate Cox 








Age, years, mean (SD) 61.1 (14.7) 68.7 (9.6) 0.410
Male, n (%) 37 (55) 30 (61) 0.008
Any comorbidity, n (%) 43 (64) 42 (88) 0.601
Diabetes mellitus type 2 14 (21) 20 (41) 0.778
Hypertension 23 (34) 26 (53) 0.409
Coronary heart disease 9 (13) 8 (16) 0.064
Heart failure (systolic/diastolic) 4 (6) 10 (20) 0.501
Prior chronic kidney disease 8 (12) 18 (37) 0.002
Peripheral artery disease 10 (15) 8 (16) 0.021
Cerebrovascular accident 6 (9) 3 (6) 0.369
COPD 8 (12) 10 (20) 0.002
Surgical (otherwise medical), n (%) 27 (40) 6 (12) 0.930
Sepsis origin, n (%)
Abdominal sepsis 31 (46) 12 (25) 0.809
Pneumosepsis 14 (21) 21 (43) 0.914
Others 22 (33) 16 (33) 0.883
Hemodynamics, mean (SD)
Lactate level, mmol/L 6.9 (5.6) 2.9 (3.1) 0.560
Noradrenaline, µg/kg/min 0.96 (0.73) 0.28 (0.36) 0.943
Mean arterial pressure 69 (15) 77 (18) 0.015
SOFA at start of treatment 13.8 (2.8) 12.8 (3.2) 0.164
CRRT, continuous renal replacement therapy; sIPTW, stabilized inverse probability of treatment weights. 
* Table 1 characteristics have been previously published elsewhere [10].
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regression model showed a slight weaker χ2 and noradren-
aline was not significantly associated with outcome (HR 
2.86, 95% CI: 0.99–8.21, p = 0.051). The final model (Ta-
ble 2) had a Harrell C-statistic of 0.80 (SE 0.04, p < 0.001) 
for mortality prediction in the long term, but also in the 
short term (28-day mortality C-statistic 0.81, SE 0.04, p < 
0.001). For a simple and practical approach, the most im-
portant factor from this model was selected for mortality 
prediction: it was observed that a lactate level cutoff of 6.0 
mmol/L (HR 3.1, SE 0.33, p < 0.001) had the highest speci-
ficity (79%) and sensitivity (58%) sum and positive predic-
tive value (79%) for long-term mortality, Harrell C-statistic 
0.67 (95% CI: 0.54–0.80, p = 0.013). Figure 2 shows the Ka-
plan-Meier curve for the CytoSorb cohort stratified by lac-
tate below or above 6.0 mmol/L. This same cutoff of lactate 
level also had the highest sensitivity (63%) and specificity 
(77%) for 28-day mortality where the positive predictive 
value was slightly lower (71%).
Discussion
In this long-term follow-up study, we have shown that 
long-term survival with either CytoSorb or CRRT beyond 
28 days of ICU admission is achievable. In a weighted anal-
ysis, CytoSorb showed an improved long-term outcome 
sIPTW
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Fig. 1. Survival plots for CytoSorb versus 
CRRT therapy without sIPTW (a) and with 
sIPTW (b). CRRT, continuous renal re-
placement therapy; sIPTW, stabilized in-
verse probability of treatment weights; 
aHR, adjusted hazard ratio.
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Table 2. Cox regression analysis for all-cause mortality in CytoSorb-treated patients
Variables at start of therapy Univariable model Full multivariable model 
(forced)
Final multivariable model
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age per 10 years older 1.53 (1.16–2.01) 0.003 – –
Any comorbidity* 2.97 (1.35–6.52) 0.007 – –
Yes, age per 10 years older – 2.53 (1.12–5.72) 0.025 2.60 (1.22–5.52) 0.013
No, age per 10 years older – 1.05 (0.73–1.50) 0.808 1.04 (0.75–1.45) 0.817
Ethnicity 1.21 (0.59–2.47) 0.606 – –
Female gender 0.89 (0.47–1.68) 0.715 – –
Body mass index 0.97 (0.92–1.02) 0.213 – –
CRRT duration 0.94 (0.86–1.03) 0.201 – –
Log creatinine 0.76 (0.25–2.25) – – –
SOFA 1.15 (1.03–1.29) 0.014 1.08 (0.95–1.22) 0.275 –
MAP 0.99 (0.96–1.01) 0.197 1.01 (0.98–1.04) 0.532 –
Log10lactate level 4.14 (1.58–10.86) 0.004 4.15 (1.13–15.3) 0.033 5.05 (1.77–14.4) 0.002
Log10noradrenaline, yr/kg/min 3.13 (1.28–7.65) 0.012 1.46 (0.44–4.80) 0.536 –
Noradrenaline duration 1.02 (0.97–1.08) 0.393 – –
Admission ICU to treatment 1.01 (0.91–1.11) 0.913 – –
Admission hospital to treatment 1.02 (0.96–1.09) 0.517 – –
Surgery 0.57 (0.29–1.14) 0.113 0.96 (0.42–2.21) 0.924 –
Type of sepsis
Pneumosepsis 1.69 (0.81–3.51) 0.159 0.78 (0.29–2.12) 0.623 –
Abdominal sepsis 0.62 (0.32–1.19) 0.152 0.41 (0.18–0.98) 0.044 0.34 (0.17–0.70) 0.004
CRRT, continuous renal replacement therapy; MAP, mean arterial pressure; ICU, intensive care unit. Any comorbidity (n = 43, 64%): 
hypertension (n = 23, 34%), prior heart failure (n = 4, 6%), chronic kidney (any KDIGO class) disease including hemodialysis (n = 8, 
12%), peripheral artery disease (n = 10, 15%), chronic obstructive lung disease (n = 8, 12%), diabetes mellitus type 2 (n = 14, 21%), 
coronary artery disease (n = 9, 13%), and cerebrovascular accident (n = 6, 9%). Note that these factors on their own do not show 















Fig. 2. Survival plot within CytoSorb-treat-




compared to CRRT alone. In CytoSorb-treated patients, it 
was observed that age, lactate level at the start of therapy, 
presence of any comorbidity, and abdominal sepsis were 
factors associated with long-term and also short-term all-
cause mortality. This is the first study to show that the ben-
efit achieved with CytoSorb in the first month of ICU ad-
mission is enduring in the long term and that a lactate level 
above 6.0 mmol/L is an important determinant of outcome.
It is currently not known what the best timing for Cy-
toSorb therapy in septic shock is. In the current study, we 
have shown that lower levels of lactate or noradrenaline 
were associated with an improved outcome. A lactate lev-
el above 6.0 mmol/L had a positive predictive value for 
long-term all-cause mortality of almost 80%. Indeed, this 
is a retrospective analysis and confounding by indication 
may have an impact on the current data. Nevertheless, it 
was observed that patients more often were treated with 
CytoSorb as a last-resort option when lactate and nor-
adrenaline levels were already (too) high, as >50% of the 
CytoSorb-treated patients already had lactate levels above 
6.0 mmol/L at the start of treatment. In line with our find-
ings, a current report also showed that initiation of Cyto-
Sorb within 48 h of admission was associated with better 
outcome [16]. Given these lines of evidence, it seems rea-
sonable to suggest that CytoSorb should be initiated ear-
lier in the disease course rather than in case of refractory 
sepsis with high lactatemia. The timing should be further 
evaluated in future studies.
As was shown in our previous publication, before apply-
ing weights CytoSorb-treated patients were not comparable 
to those treated with CRRT alone at the start of therapy as 
they had worse hemodynamic characteristics including 
higher levels of lactate, need for vasopressors, lower MAP, 
and higher SOFA scores. Nonetheless, they still had a simi-
lar outcome to those treated with CRRT alone. Indeed pa-
tients treated with CRRT more often showed chronic kid-
ney disease; however, this factor was not associated with 
long-term outcome in our analysis. When we applied IPTW 
adjusting for MAP, it was shown that CytoSorb-treated pa-
tients had an improved survival. Presence of chronic kidney 
disease, male gender, or other factors (peripheral artery dis-
ease or COPD) which were at imbalance did not show sig-
nificant associations with outcome.
The current data show that, not unexpectedly, the first 
days of ICU admission were most important in the deter-
mination of clinical outcome. It is important to underline 
that the 28-day mortality rate showed to be a good sur-
rogate for overall outcome as >80% of patients who sur-
vived up to 28 days after ICU admission also survived in 
the long term. There are some important limitations of 
the current study. Next to the retrospective nature of the 
study, we did not have inflammatory cytokines such as 
IL-6 or procalcitonin levels available. In addition, al-
though this is currently the largest cohort study of septic 
shock patients treated with CytoSorb analyzed for mor-
tality, the number of patients assessed is still relatively 
small and the results are partly obtained from a propen-
sity score analysis. Moreover, we were not able to perform 
an analysis for fluid balances as this would entail a dy-
namic analysis and this falls outside the scope of the cur-
rent article. The results obtained from this study should 
be further confirmed in randomized clinical trials.
In conclusion, we have shown that the survival achieved 
with both CRRT and CytoSorb for patients with septic 
shock leads to an improved outcome beyond 28 days of 
ICU admission and may be enhanced for CytoSorb treat-
ment. Importantly, lactate levels above 6.0 mmol/L were 
predictive for mortality with a 79% specificity and 80% 
positive predictive value. Therefore, for patients with sep-
tic shock not responding to fluid therapy and with a lac-
tate level below 6.0 mmol/L, CytoSorb therapy should be 
considered, especially for young patients with abdominal 
sepsis. Future randomized trials should take into account 
this lactate level since too high lactate levels are associated 
with poor treatment response.
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